A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics

Highlights • p53 expression is a prognostic factor for MDS patients treated with azacitidine. • Immunohistochemistry of p53 can be a simple method to analyze bone marrow clot. • Combination of cytogenetics and p53 expression can make short-term prognoses.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2016-02, Vol.41, p.21-26
Hauptverfasser:	Nishiwaki, Satoshi, Ito, Masafumi, Watarai, Rie, Okuno, Shingo, Harada, Yasuhiko, Yamamoto, Satomi, Suzuki, Kotaro, Kurahashi, Shingo, Iwasaki, Toshihiro, Sugiura, Isamu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antimetabolites, Antineoplastic - therapeutic use Azacitidine Azacitidine - therapeutic use Biomarkers, Tumor - analysis Chromosome Aberrations Female Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Kaplan-Meier Estimate Male Middle Aged Myelodysplastic syndrome Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - mortality p53 Prognosis Prognostic index Treatment Outcome Tumor Suppressor Protein p53 - biosynthesis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • p53 expression is a prognostic factor for MDS patients treated with azacitidine. • Immunohistochemistry of p53 can be a simple method to analyze bone marrow clot. • Combination of cytogenetics and p53 expression can make short-term prognoses.
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2015.11.014